Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

* New data from 741-patient trial show those treated with Prexige experienced significantly smaller impact on blood pressure compared to ibuprofen[1]

* Many patients with osteoarthritis also have high blood pressure; even small changes in blood pressure can impact cardiovascular risk[2],[3]

* Prexige approved in more than 50 countries and currently under review in US for use in osteoarthritis patients

BASEL, Switzerland, June 15, 2007 - Patients with osteoarthritis who also have controlled hypertension experienced a slight decrease in average daily blood pressure when treated with the selective COX-2 inhibitor Prexige® (lumiracoxib) compared to a slight increase in those taking ibuprofen, a commonly-used non-steroidal anti-inflammatory drug (NSAID)[1].

These new results, presented today at the Annual European Congress of Rheumatology (EULAR) in Barcelona, are important because around 40% of patients with osteoarthritis also have high blood pressure (or hypertension)[4],[5].

Independent research shows that even small elevations in blood pressure can contribute to an increased risk of cardiovascular events[2],[3],[6],[7],[8]. Osteoarthritis is the most common form of arthritis affecting 139 million people worldwide[9].

"NSAIDs, including some COX-2s, have been associated with raised blood pressure, and this effect may be in part responsible for the increased risk of cardiovascular disease associated with this class of medications," said Tom MacDonald, Ph.D., Professor of Clinical Pharmacology at the Hypertension Research Centre at Ninewells Hospital & Medical School in Dundee, Scotland. "These data indicate that lumiracoxib may have less impact on blood pressure than the most commonly used NSAID ibuprofen."

Prexige, which is given to patients as a 100 mg once-daily tablet, is approved for use in certain types of patients with osteoarthritic pain of the knee
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... 2014  Packaging Coordinators, Inc. (PCI) is pleased to ... Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered ... United Kingdom and operates regional ... and Tokyo , Japan. Penn Pharma offers ... Commercial dosage form manufacturing, as well as Clinical Packaging, ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... Surgery Foundation Announces Speakers, Moderators and Panelists for 2nd International Symposium on MR-Guided Focused ... CHARLOTTESVILLE, Va. , June ... to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be ... , , , ...
... , SANTA BARBARA, Calif. , June 25 ... Diabetes Research Institute (Sansum) announced today the achievement of a milestone ... Foundation (JDRF). , , ... The world,s most flexible artificial pancreas system platform, currently being used ...
Cached Medicine Technology:Leading Experts to Speak at Focused Ultrasound Symposium 2Leading Experts to Speak at Focused Ultrasound Symposium 3Leading Experts to Speak at Focused Ultrasound Symposium 4Leading Experts to Speak at Focused Ultrasound Symposium 5Leading Experts to Speak at Focused Ultrasound Symposium 6JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 2JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 3JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 4JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 5JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 6
(Date:7/30/2014)... York (PRWEB) July 30, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continues to grow, Bernstein ... voice to those calling for a ban on uterine ... Debra Valverde was diagnosed with leiomyosarcoma following a hysterectomy ... a year of her diagnosis, the aggressive cancer had ...
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... a garden might help soothe the agitation that commonly strikes ... 17 past studies, British researchers found evidence that watering plants, ... some dementia patients, anxiety. The study authors cautioned that ... subject to study -- and the evidence of a benefit ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
(Date:7/30/2014)... July 30, 2014 “North America Contrast ... data on the North America Contrast Media Injectors market. ... and volume (in units) and average price data (in ... Injectors ,     Interventional Cardiology/Angio Injectors and MRI Injectors ... agent) is a substance used to enhance the contrast ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4
... risks of death are probably higher with aprotinin, a drug ... surgery, compared with lysine analogues, according to a study ... of CMAJ . , On December 3, a ... aprotinin use. The study is being early released in advance ...
... A new report from the Institute of Medicine proposes ... decrease the chances of fatigue-related medical errors and to ... The report does not recommend further reducing residents, ... week set by the Accreditation Council for Graduate Medical ...
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and ... inflammation, announced today that its Board of Directors ... Corporation ("Westaim"), a requisition to call a special ... capital of US$0.80 per share to NUCRYST shareholders. ...
... Health System Builds Resilient, Cost and Energy Efficient Information ... Mass., Dec. 2 EMC Corporation (NYSE: ... today announced that the Daughters of Charity Health System ... California coast, has consolidated storage and servers and implemented ...
... Randomized Comparator Study to Evaluate Efficacy of Commercially ... , WOODCLIFF LAKE, N.J., Dec. 2 ... that it plans to initiate the first clinical ... injection) compared to Vidaza(R) (azacitidine) in adult patients ...
... Dec. 2 Barotz Dental is now one of only ... This is the only laser gum treatment protocol that ... bone tissue around teeth. , ... height of the tissue around teeth, minimizes pain and discomfort ...
Cached Medicine News:Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2
... Oxylab pO2 probes feature response ... seconds for real-time monitoring of ... Oxylab LDFTM, measurements of pO2, ... be obtained from the same ...
Spherical Burr for FR030R, 5 mm....
Tungsten Carbide Burr "HM", 0,7 mm, ISO-No. 007....
"Rosen" burr, 0,7 mm, ISO-No. 007....
Medicine Products: